Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin alfa
- Development stage
- Approved
- Lead developer
- Merck KGaA
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Follitropin alfa is a recombinant form of human follicle-stimulating hormone (FSH), produced using genetically engineered Chinese hamster ovary (CHO) cells. It consists of two non-covalently linked glycoprotein subunits (alpha and beta) that are structurally identical to endogenous human FSH. Follitropin alfa acts by binding to the Follicle-stimulating hormone receptor on ovarian granulosa cells in women and testicular Sertoli cells in men. This stimulates ovarian follicular growth and maturation in women with ovulatory dysfunction or undergoing assisted reproductive technology (ART), such as IVF or embryo transfer. In men with hypogonadotropic hypogonadism, it promotes spermatogenesis when used after pretreatment with human chorionic gonadotropin (hCG). The drug is indicated for multifollicular development during ART procedures and for induction of ovulation or spermatogenesis where infertility is not due to primary gonadal failure[1][2][3][5][6].
- Brand names
- Gonal-FGonal-F RFFGonal-F RFF Redi-jectBemfolaFollistimOvaleapPuregon
- Other names
- recombinant human follicle stimulating hormoner-hFSH
02
Targets
FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on follitropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin alfa.